Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 3/20 | 0.39 |
| ▸ | GSR | P00390 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.34 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.34 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10995454 | 0.88 | TRPA1 (0.43) | LMNATRPA1KDM4EAOC3ALDH1A1 | |
| SCHEMBL10338422 | 0.85 | THRB (0.46) | LMNATRPA1GSRKDM4EL3MBTL1 | |
| SCHEMBL13743571 | 0.82 | SLC6A4 (0.39) | LMNATRPA1GSRKDM4EL3MBTL1 | |
| SCHEMBL27906584 | 0.82 | SLC6A4 (0.39) | LMNATRPA1GSRKDM4EL3MBTL1 | |
| SCHEMBL28635640 | 0.81 | TAAR1 (0.42) | LMNAKDM4EALDH1A1TSHRSLC6A2 | |
| SCHEMBL16004892 | 0.80 | LMNA (0.44) | LMNATRPA1GSRKDM4EL3MBTL1 | |
| SCHEMBL12929842 | 0.80 | LMNA (0.44) | LMNATRPA1GSRKDM4EL3MBTL1 | |
| SCHEMBL7294407 | 0.79 | AOC3 (0.38) | LMNAMAPK1AOC3TSHRPOLB | |
| SCHEMBL11641922 | 0.79 | PPARG (0.40) | KDM4EALDH1A1TSHR | |
| SCHEMBL7643899 | 0.77 | CYP2D6 (0.35) | LMNATRPA1GSRKDM4EL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9452117-B2 | Nitrate esters and their use for the treatment of muscle and muscle related diseases | THE CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY (US) | 2016-09-27 | — | — | US | disclosed |
| EP-2329862-B1 | Nitrate esters and their use for the treatment of muscle and muscle related diseases | CHARLOTTE MECKLENBURG HOSPITAL (US) | 2016-03-30 | — | — | EP | disclosed |
| US-9023890-B2 | Nitrate esters and their use for the treatment of muscle and muscle related diseases | THE CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY (US) | 2015-05-05 | — | — | US | disclosed |
| US-20120309825-A1 | Nitrate Esters And Their Use For The Treatment Of Muscle And Muscle Related Diseases | THE CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY D/B/A CAROLINAS MEDICAL CENTER (US) | 2012-12-06 | — | — | US | disclosed |
| EP-2529734-A1 | Nitrate esters and their use for the treatment of muscle and muscle related diseases | The Charlotte-Mecklenburg Hospital Authority (US) | 2012-12-05 | — | — | EP | disclosed |
| US-8106080-B2 | Mixture of muscle relaxant and nitrogen oxide doner; promote cell muscle proliferation repair; muscle dystrophy therapy | WANG, GUQI (CA) | 2012-01-31 | — | — | US | disclosed |
| EP-2329862-A1 | Nitrate esters and their use for the treatment of muscle and muscle related diseases | The Charlotte-Mecklenburg Hospital Authority (US) | 2011-06-08 | — | — | EP | disclosed |
| US-20110130455-A1 | Nitrate Esters and Their Use For The Treatment of Muscle and Muscle Related Diseases | THE CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY D/B/A CAROLINAS MEDICAL CENTER | 2011-06-02 | — | — | US | disclosed |
| US-20080207713-A1 | Compositions and Methods For Enhancing Nitric Oxide Delivery | ANDERSON, JUDITH E. (CA) | 2008-08-28 | — | — | US | disclosed |
| WO-2006130982-A1 | COMPOSITIONS AND METHODS FOR ENHANCING NITRIC OXIDE DELIVERY | UNIVERSITY OF MANITOBA (CA) | 2006-12-14 | — | — | WO | disclosed |
| EP-0328714-B1 | STABILIZED OXYMETHYLENE COPOLYMER COMPOSITION | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1993-05-12 | — | — | EP | disclosed |
| EP-0328714-A1 | Stabilized oxymethylene copolymer composition | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1989-08-23 | — | — | EP | disclosed |
| US-4792579-A | ALKALINE EARTH METAL SALT OF AN ESTER OF A TRIBASIC INORGANIC ACID OF AN ORGANIC CARBOXYLIC ACID MONOESTER OF AN ALCOHOL HAVING TWO OR MORE HYDROXYL GROUPS | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1988-12-20 | — | — | US | disclosed |
| US-4182706-A | Flame-retardant agents for phenolic resins and process for their production | CHEMISCHE FABRIK KALK GMBH (DE) | 1980-01-08 | — | — | US | disclosed |
| US-4182706-A | Flame-retardant agents for phenolic resins and process for their production | CHEMISCHE FABRIK KALK GMBH (DE) | 1980-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207713-A1 | Compositions and Methods For Enhancing Nitric Oxide Delivery | TNNC1, NOS1, NOS3 | LMNA 742/4885TRPA1 1138/4885GSR 210/4885 |
| US-20120309825-A1 | Nitrate Esters And Their Use For The Treatment Of Muscle And Muscle Related Diseases | TNNC1, TNNI3, TNNT2 | LMNA 568/4885TRPA1 3986/4885GSR 758/4885 |
| US-20110130455-A1 | Nitrate Esters and Their Use For The Treatment of Muscle and Muscle Related Diseases | TNNC1, TNNI3, TNNT2 | LMNA 613/4885TRPA1 3948/4885GSR 804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.